Objectives-To examine how insurance companies assess proposals for life assurance from applicants with raised cholesterol concentrations and to determine the excess mortality rating applied.
Introduction
Screening programmes have costs as well as benefits. The psychological costs of screening have recently been reviewed,'-but the potential financial costs to the patient should not be forgotten. Finding a raised cholesterol concentration may result in a less favourable life assurance risk rating and a correspondingly higher premium. Although it is widely appreciated that risk factors for coronary heart disease, such as smoking and high blood pressure, may result in higher premiums, the corresponding implications for cholesterol screening seem to be less clearly understood both by patients and by their doctors. This may be partly explained by inconsistencies among insurance companies in their assessment of the excess mortality risk associated with hypercholesterolaemia.
The normal premium rates charged by life assurance companies are based on the past mortality experience of policy holders who have been accepted at standard rates. The usual practice in underwriting applications for life assurance is to use a numerical rating system to estimate the effect of various risk factors on this assumed rate of mortality. For example, smoking or hypertension would be regarded as a risk factor. An increase in the assumed rate of mortality would be expressed in percentage terms-for example, 50% above normal mortality, which would reduce the expectation of life for a 30 year old man from 44-9 to 41 0 years. If the increase is significant in monetary terms the policy premium would be increased.
We report a survey of 49 insurance companies, which examined how companies assess proposals from applicants with hypercholesterolaemia and what level of excess mortality rating was applied.
Methods
A list of around 90 insurance companies thought to underwrite life assurance policies was compiled from several sources, including the Oxford University appeals office. A personal letter was sent to the managing director of each company explaining the survey. It inquired specifically whether applicants were required to disclose the results of cholesterol measurements, how the company assessed proposals from applicants with raised values, and whether different policies were applied to men and women. The results of the preliminary survey allowed us to exclude companies that did not underwrite life assurance or were subsidiaries of larger groups and to identify companies engaged in reassurance (a method of spreading a risk among companies because of its size or nature). We then sent a second, more detailed questionnaire to the remaining companies. They were asked to assess the excess mortality rating which would be applied to proposals from four fictional male applicants, each aged 30, seeking a 20 year term policy paying benefit only on death. The excess mortality rating was defined as the percentage increase over the assumed rate of mortality. Table I gives the details of each proposal. Subjects 1 and 2 had differing concentrations of total cholesterol but no other risk factors for coronary heart disease. Subject 3 had a total cholesterol concentration of 8 Forty seven of the 49 companies stated that thev applied the same criteria to both men and women when assessing proposals. Several pointed out that the basic premium already reflected the lower aggregate risk in women. Two companies, however, apparently made a distinction between men and women, one accepting a higher proportion of applications from women without further investigation and the other taking "a more lenient view of a raised cholesterol level in women, particularly if the assurance to be effected was for a limited term."
There was complete agreement that an applicant with a borderline cholesterol concentration of6 4 mmol/l and no other cardiovascular risk factors (subject 1; table I) should incur no excess mortality rating. The figure shows the responses to the proposals for subjects 2-4. For subject 2, whose mean total cholesterol concentration was 8-1 mmol/l, the distribution of excess mortality rating was fairlv narrow (median 50%, range 0-75%), and 40 companies (95%) applied an excess of 50% or less. Most companies imposed a substantial excess on subject 3 (median 135%, range 50-200n0 lipoprotein or the ratio of total to high density lipoprotein cholesterol. Some reduction in risk rating may also be allowed for a response to treatment and for the absence of other cardiovascular risk factors. The excess mortality rating applied to raised triglyceride concentrations varies. Some reassurance manuals disregard triglyceride concentrations unless they exceed 20 mmol/l and base their estimate of the excess mortality on the underlying cause of-hypertriglyceridaemia whereas others impose an excess for concentrations exceeding 4-0 mmol/l. In calculating the excess rating an additive rather than multiplicative model is usually used to allow for the effect of other risk factors such as smoking or hypertension. The various criteria used by different companies resulted in considerable variability in the excess mortality risk applied to proposals from applicants with clearly raised cholesterol concentrations. No excess was applied to a proposal from a 30 year old applicant with a total cholesterol concentration of 6 4 mmol/l, which is about 0 5 mmol/l higher than the mean reported in a recent population survey in Britain. 4 By contrast, when the total cholesterol concentration was 8 1 mmol/I but no other cardiovascular risk factors were present a small but variable excess was applied. In this instance, the proposal would probably be accepted at normal rates because the extra premium resulting from the small excess mortality rating of 50% or less applied by most companies would be too little to be worth imposing. The limited available evidence suggests that a cholesterol concentration of this level confers a 21/2-fold to threefold higher risk of fatal coronary heart disease for men than does a concentration equal to the population mean89 and an excess mortality rating of 75% might therefore be more appropriate (an additional 25% should be added to the excess ratings shown in table II for men aged 30 or more and 50% for younger men (R D C Brackenridge, personal communication)). When multiple cardiovascular risk factors were present the same cholesterol concentration of 8 1 mmol/l attracted a much higher but variable excess mortality risk in an overweight hypertensive male smoker. The large variation in excess mortality applied may partly be explained by individual differences in the excess applied for each cardiovascular risk factor by different companies. There was also a wide variation in the excess mortality applied to a proposal from an applicant with severe hypercholesterolaemia in whom the presumptive diagnosis was possible familial hypercholesterolaemia. It was surprising that some companies applied either no excess or only a small excess as epidemiological data suggest that the cumulative probability of fatal or nonfatal coronary heart disease is at least a third by the age of 50 in men with familial hypercholesterolaemia.'°' I The In conclusion, although explicit criteria are used by insurance companies to assess the excess mortality associated with raised cholesterol concentrations, we found considerable variation in the excess rating applied. The limitations of the data on which ratings are based make an exact assessment of the risk associated with moderately increased cholesterol concentrations difficult. It was, however, surprising to find that some companies applied little or no excess mortality to applicants with possible familial hypercholesterolaemia as there is a high cumulative probability of premature coronary heart disease associated with this condition. The implications of our findings are largely restricted to patients with severe hypercholesterolaemia and, in particular, to those with familial hypercholesterolaemia, which affects about 0 2% of the population. Higher term life assurance premiums are likely to be applied by many companies to proposals from these patients. In the absence of other cardiovascular risk factors more mild hypercholesterolaemia is unlikely to result in increased term assurance premiums at present.
